Search Results
Your search for ,ShE matches 5598 pages
Showing 1301 - 1350Risk-Reducing Bilateral Mastectomy May Help Women With High-Penetrance Genetic Mutations to Avoid Cancer
“Risk-reducing bilateral mastectomy allows a woman with a high-penetrance breast cancer-causing mutation to avoid an encounter with the experience of breast cancer diagnosis and treatment,” Seema A. Khan, MD, MPH, stated at the 2022 Lynn Sage Breast Cancer Symposium.1 For these women, by avoiding...
From the Clinic to the Lab: Overcoming Resistance to Immune Checkpoint Therapy
As a result of breakthroughs in immune checkpoint inhibitors over the past decade, immunotherapy has joined surgery, radiation therapy, and chemotherapy as one of the pillars of cancer treatment. However, nearly half of patients still do not benefit from immune checkpoint blockade. During the 2022...
Expert Point of View: Neelima Vidula, MD
Commenting on the DESTINY-Breast03 presentation at the 2022 San Antonio Breast Cancer Symposium, Neelima Vidula, MD, a medical oncologist at Mass General Cancer Center, said: “The results highlight the important survival differences of T-DXd [fam-trastuzumab deruxtecan-nxki] compared to T-DM1...
T-DXd Confirmed as Preferred Second-Line Therapy for Metastatic HER2-Positive Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) proved to be superior to the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1), significantly improving progression-free survival and overall survival, in women with unresectable or metastatic HER2-positive breast cancer as ...
How the American Cancer Society Aims to Improve Outcomes in Breast and Cervical Cancers and Reduce Health Disparities
Just days before the publication of the 2022 Annual Report to the Nation on the Status of Cancer on October 27, 2022,1 which showed a continued downward trend in cancer deaths, Karen Knudsen, MBA, PhD, Chief Executive Officer of the American Cancer Society (ACS), joined the First Lady Dr. Jill...
Ribociclib Plus Endocrine Therapy vs Combination Chemotherapy for Patients With Breast Cancer: Focus on Those in Visceral Crisis
According to findings from the phase II RIGHT Choice trial, many premenopausal patients with metastatic hormone receptor–positive, HER2-negative breast cancer experiencing visceral crisis are best treated with first-line ribociclib plus endocrine therapy rather than with chemotherapy.1 Ribociclib,...
In Stage IV NSCLC, Anti-TIGIT Antibody Boosts Immunotherapy Benefit
In the phase II ARC-7 study, when domvanalimab, a novel antibody that blocks T-cell immunoglobulin and ITIM domain (TIGIT), was added to immunotherapy for patients with stage IV non–small cell lung cancer (NSCLC), the combination resulted in improved response rates and progression-free survival...
Cedars-Sinai Cancer Leaders Assume New Roles
Lali Medina-Kauwe, PhD, former Co-Leader of the Cancer Biology Program in Cedars-Sinai Cancer, assumed a new role as Associate Director for Basic Research. The Cancer Biology Program will now be led by Dolores Di Vizio, MD, PhD, Professor of Biomedical Sciences, Pathology and Laboratory Medicine in ...
How Do You Move Forward With a Life You Didn’t Choose After a Cancer Diagnosis?
“I was in bed in the surgical wing of Duke University Hospital when the doctor popped his head in and smiled apologetically before flicking on the fluorescent lights. It was 4:00 AM, the end of my second night in the hospital, but nobody sleeps in the conventional sense,” writes Kate Bowler in the...
A Serendipitous Ride Along a Highway May Have Saved My Life
In 2017, I noticed a roadside billboard touting the benefits of low-dose computed tomography (CT) imaging for lung cancer screening. The message probably saved my life. The public service campaign, called Saved by the Scan from the American Lung Association, included an Internet address where I...
Robin Zon, MD, FACP, FASCO, Elected ASCO President for 2024–2025 Term
ASCO has elected Robin Zon, MD, FACP, FASCO, a long-time member and volunteer, to lead as its President beginning in June 2024. Dr. Zon will take office as President-Elect immediately following the ASCO Annual Business Meeting in Chicago on June 5, 2023. Five additional members were also elected to ...
From Immigrant Roots to a Budding Career in Oncology, Gladys Magaly Rodriguez, MD, Aims to Advance Health Equity in Vulnerable Populations
Gladys Magaly Rodriguez, MD, was born in Piedras Negras, Mexico, a city situated along the banks of the Rio Grande. At age 6, her family immigrated to Eagle Pass, Texas, a border town of some 30,000 people that is predominantly Latinx and Spanish speaking. “Even though I lived and attended school...
Alex Herrera, MD, Finds a Path From the Baseball Fields of Miami to a Leadership Role at City of Hope
Lymphoma expert Alex Herrera, MD, was born in Miami; his parents were just 19 years old when he was born. Dr. Herrera’s father was born in Puerto Rico to Cuban and Ecuadorian parents. His mother was born in Cuba and came to the United States via Operation Peter Pan, the clandestine program that...
Indiana University Names Music Therapy Researcher Sheri Robb, PhD, as New Walther Professor of Supportive Oncology
Indiana University (IU) School of Medicine has named Sheri Robb, PhD, a Walther Professor of Supportive Oncology. This is one of five endowed positions to develop a supportive oncology program that encompasses research and patient care. Dr. Robb is a nationally renowned music therapy researcher,...
Efficacy of Sacituzumab Govitecan in TROPiCS-02 Trial Not Dependent on Trop-2 Expression
The latest analysis of the TROPiCS-02 breast cancer trial shows that sacituzumab govitecan-hziy is effective in patients with a wide range of Trop-2 expression levels. The findings were reported at the 2022 San Antonio Breast Cancer Symposium by Hope S. Rugo, MD, FASCO, Professor of Medicine and...
Pregnancy Confers ‘Dual Effect’ on Breast Cancer Risk
“Pregnancy confers a dual effect” on breast cancer risk, “with an initial transient increased risk for breast cancer that is followed by long-term protection over time,” Luis Zabala Blanco, Jr, MD, noted in an update on the pathology of pregnancy-associated breast cancer, which was presented at the ...
Heartbreak and a Second Chance at Love and Life
“I knew my husband was dying in June. He’d been living with a terminal diagnosis for 6 years, but suddenly his cancer turned aggressive…. The last time we saw the oncologist, he sent us home with a DNR order and told me to put it on the refrigerator, because that’s where the EMTs look,” writes...
World Travel Helped Brittany L. Bychkovsky, MD, MSc, Shape Her Global Commitment to Breast Cancer Care
Breast cancer specialist Brittany L. Bychkovsky, MD, MSc, grew up primarily in Kansas; however, given that her father was a pilot, her childhood was not wholly centered in the Sunflower State. “When I was 12 years old, my mom, who was a schoolteacher, was diagnosed with stage III breast cancer. Her ...
The Effect of the Reversal of Roe v Wade on Care of Pregnant Women With Cancer
The repercussions from the decision by the U.S. Supreme Court on June 24, 2022, to overturn Roe v Wade, effectively ending a nearly 50-year federal constitutional right to an abortion and allowing instead states to determine abortion access, are starting to be felt in the cancer care community. The ...
Michael A. Caligiuri, MD, Traveled From Humble Beginnings to a Notable Career as an Oncology Leader
In this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Michael A. Caligiuri, MD, a physician-scientist who currently serves as President of the City of Hope National Medical Center and the Deana and Steve Campbell Physician-in-Chief...
Legal and Ethical Use of Complementary and Alternative Medicine Interventions in Oncology
In addition to, or instead of, receiving therapies that are the standard of care, patients with cancer sometimes request to receive complementary (therapies used in conjunction with standard cancer treatment) and alternative (nonstandard treatments used in place of standard cancer treatment)...
Expert Point of View: Erica Michelle Stringer-Reasor, MD
Invited discussant Erica Michelle Stringer-Reasor, MD, Associate Professor of Medicine and Director of the Breast Cancer Program at the O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, said the exploratory analysis of KEYNOTE-522 established the value of using residual...
Expert Point of View: Véronique Diéras, MD
The invited discussant of the phase I/II study of patritumab deruxtecan (HER3-DXd) was Véronique Diéras, MD, of the Eugène Marquis Centre, Rennes, France. She commented that HER3-DXd showed promising activity across breast cancer subtypes with heavily pretreated metastatic breast cancer. She...
Capturing Tumor Evolution With Serial Biopsies May Guide Treatment Changes to Benefit Patients With Breast Cancer
Molecular testing and genomic testing are now considered standard of care in breast cancer, guiding treatment decisions in early breast cancer and targeted therapies in the metastatic setting. “But tumors evolve,” Virginia Kaklamani, MD, DSc, reminded participants at the 2022 Lynn Sage Breast...
Expert Point of View: Therese M. Mulvey, MD, FASCO
Discussant of the abstract on electronic symptom management, Therese M. Mulvey, MD, FASCO, Director of Breast Oncology at the Massachusetts General Hospital North Shore Cancer Center, Boston, said the SIMPRO study showed that electronic patient-reported outcomes can be implemented into real-world...
Patient-Reported Outcomes Study Finds Severe Symptoms in Meaningful Minority of Patients With Cancer
Routine monitoring in the real world may help to identify patients with cancer who are experiencing challenging symptoms, without significantly disrupting clinical workload, according to data presented during the 2022 ASCO Quality Care Symposium.1,2 The analysis of nearly 40,000 patient-reported...
Expert Point of View: Jean Lundberg Wright, MD
Invited discussant of the October 2022 ASCO Plenary session, Jean Lundberg Wright, MD, commended the authors on an “extremely well-done study, with findings applicable to patients today in clinics where barriers are not prohibitive.” She also noted several limitations to the currently available...
T-DXd Yields Longer Overall Survival than T-DM1 as Second-Line Treatment in Patients With HER2-Positive Metastatic Breast Cancer: DESTINY-Breast03
Second-line treatment with fam-trastuzumab deruxtecan-nxki (T-DXd) led to significantly longer overall survival compared with ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated results from the DESTINY-Breast03 phase III clinical trial...
Expert Point of View: Iris C. Gibbs, MD, FACR, FASTRO and Sophia C. Kamran, MD
Iris C. Gibbs, MD, FACR, FASTRO, of Stanford Medicine in California and Chair of the American Society for Radiation Oncology (ASTRO) Council on Health Equity, Diversity, and Inclusion, was an invited discussant for this study on physician assessment of sexual dysfunction in women vs men receiving...
Sexual Side Effects of Radiotherapy for Genitourinary Cancers: Is Physician Assessment Equitable for Women and Men?
Many radiation oncologists tend to discuss the sexual side effects of radiation therapy, specifically brachytherapy, with men more often than with women, according to a two-part study reported at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 At a high-volume cancer...
Neoadjuvant T-DXd Shows Clinical Activity in Patients With HER2-Low Breast Cancer
Patients with localized, hormone receptor (HR)-positive, HER2-low breast cancer treated with fam-trastuzumab deruxtecan-nxki (T-DXd) in the neoadjuvant setting had an overall response rate of 75% without combining the agent with anastrozole and 63% in combination with anastrozole, according to...
NRG/RTOG 1112: Radiotherapy Added to Sorafenib Improves Survival in Advanced Hepatocellular Carcinoma
Stereotactic body radiation therapy (SBRT) given prior to sorafenib improved overall survival, progression-free survival, and time to disease progression in patients with unresectable advanced hepatocellular cancer vs sorafenib alone, including those with macrovascular invasion, according to the...
Cancer Drugs and Price Controls: Is It Time?
According to a recent article published in Cancer Epidemiology, Biomarkers & Prevention, cancer care in the United States exceeded $208 billion in 2020 and is expected to surpass $240 billion by 2030.1 These estimates are driven largely by a growing and aging population. The expenditures...
How the Pancreatic Cancer Early Detection Consortium Aims to Advance Survival Rates in This Deadly Disease
The statistics are grim: Worldwide, pancreatic cancer is the 12th most common cancer and the seventh leading cause of cancer mortality.1 In the United States, the malignancy has the highest mortality rate of all major cancers. It is currently the third leading cause of cancer-related death after...
Expert Point of View: Sophia C. Kamran, MD
Formal discussant of the PCS5 trial, Sophia C. Kamran, MD, Director of Diversity, Equity, and Inclusion, Department of Radiation Oncology at Massachusetts General Hospital and Assistant Professor of Radiation Oncology at Harvard Medical School, said the goal of trials like this one is to optimize...
Study Finds Racial Disparity in Prometastatic Tumor Microenvironment Among Patients With Residual Breast Cancer After Neoadjuvant Chemotherapy
Residual tumors from Black patients with estrogen receptor–positive/HER2-negative primary breast cancer treated with neoadjuvant chemotherapy had a higher risk score associated with a biomarker of distant metastatic recurrence compared with tumors from White patients, according to new findings...
Study Examines Coping Strategies Used by Caregivers of Patients Undergoing Stem Cell Transplants
November is Caregiver Awareness Month, and timely findings from a study published by Amonoo et al in the journal Blood Advances suggested that, among caregivers of patients undergoing a stem cell transplant, how someone approaches coping can influence the levels of anxiety, depression, and poor...
High Sugar Consumption May Be Linked to Increased Risk of Premature Aging in Pediatric Cancer Survivors
Survivors of pediatric cancer who consumed more total sugar, added sugar, and sugar-sweetened beverages had more aging-related health conditions than survivors who consumed less sugar, according to a new study presented by Lan et al at the American Association for Cancer Research (AACR) Special...
Patients Who Are HIV-Positive and Have Cancer May Have Accelerated Epigenetic Aging
Patients with cancer who are living with the human immunodeficiency virus (HIV) infection had an increased epigenetic age compared with patients with cancer living without the HIV infection, according to a new study presented by Coghill et al at the American Association for Cancer Research (AACR)...
Breast Cancer Advocate and Chief of Surgical Oncology at Howard University, Lori Wilson, MD, FACS, Dies
Lori Wilson, MD, FACS, was the first woman to hold the surgical oncology division chief position at Howard University Hospital and the first woman to be promoted to full professor in surgery at Howard University College of Medicine. Known as a fierce advocate for patients with cancer in underserved ...
A Laryngectomy Altered How I See Myself in the World
There is a 2-decades-long separation between the time I was diagnosed with oropharyngeal squamous cell carcinoma in 1996 and my laryngectomy in 2016. The surgery was necessary because of the long-term damage to my larynx from the radiation therapy I received. In 1996, I had a low-grade sore throat...
Before Becoming a Leader in Multiple Myeloma Research, Sarah A. Holstein, MD, PhD, Considered a Career in Music
Myeloma expert Sarah A. Holstein, MD, PhD, was born and reared in Iowa City, a college town in eastern Iowa along the banks of the Iowa River. “The town itself is small, but it doubles in population when all the college students are present. Both my parents had a PhD in humanities, so I had no...
ASCO Publishes Rapid Guideline Update on PARP Inhibitors in Ovarian Cancer
An ASCO guideline rapid update is revising guidance for the use of poly (ADP-ribose) polymerase (PARP) inhibitor therapy for the management of ovarian cancer to include updated considerations for the use of several different PARP inhibitor therapies based on recent phase III clinical trial data.1...
Building a New Normal: Symptom Self-Management Intervention May Benefit Cancer Survivors
An easy-to-deploy, automated self-management intervention may prove to be of benefit in supporting competence and symptom management among cancer survivors, according to data presented during the 2022 ASCO Quality Care Symposium.1 Analysis of the randomized controlled trial found that 12 months...
New Leadership Elected to the American Society of Hematology
The American Society of Hematology (ASH) recently announced the election of four new members to its Executive Committee for terms beginning after the 2022 ASH Annual Meeting & Exposition in December in New Orleans. Belinda R. Avalos, MD, will serve a 1-year term as Vice President, followed...
Importance of Screening Programs in Diagnosing Cancer in Patients With Type 2 Diabetes
Researchers have discovered that patients with type 2 diabetes who develop cancer are more likely to be diagnosed with advanced disease if they do not undergo routine screenings, according to a new study published by Jansana et al in the European Journal of Cancer. The new findings were also...
PALLAS Trial: No Benefit Reported for Adjuvant Palbociclib in Stage IIA Hormone Receptor–Positive, HER2-Negative Breast Cancer
In a preplanned analysis of the stage IIA cohort of the PALLAS trial, the addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone. This finding suggests this agent provides no benefit in reducing the risk of early relapse in patients with ...
Short Course of Radiotherapy With Concurrent Radiation Boost for High-Risk, Early-Stage Breast Cancer
A 3-week course of radiation therapy including a concomitant boost of radiation to the surgical site appears to be as safe and effective as 4 to 6 weeks of radiation therapy given with a sequential boost of radiation for patients with early-stage breast cancer who have a high risk of recurrence....
Gradual Increase in Daily Activity With Psychological Therapies May Improve Mental and Physical Health for Patients and Survivors of Breast Cancer
Patients and survivors of breast cancer may have better mental health, physical health, and quality of life when taking part in a “behavioral graded activity” in combination with psychological therapies, according to a new study published by Lahousse et al in the European Journal of Cancer. The new ...
CAR T-Cell Therapy Outcomes Similar Across Different Socioeconomic Levels Among Patients With Pediatric ALL
Although socioeconomic status often influences survival outcomes, pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL) who were living in poverty and were treated with CAR T-cell therapy achieved similar overall survival and were equally likely to achieve a complete...
